By 2035, will the FDA approve a drug that slows the yearly progression of Alzheimer's disease by at least 50%?
Saúde e medicinaOne-Off8a
Manifold MarketsSem KYCDados de resolução verificadosRazoavelmente calibradoAviso de qualidade dos dadosDados da fonte degradados
Dados de 26 de out. de 2026, 05:51 UTC · política pm-quality-4
Previsão da comunidade atualSim 57.1%
Previsores
8
Tipo de pergunta
binary
Metodologia
Play-money forecasting platform
Tipo de fonte
Previsão
Dados do mercado
Atualizado há 11 horas
Desatualizado14/01/25, 10:58 UTC1/01/35, 23:59 UTC
Tendências
Regras
This market will be resolved based on two main criteria by January 1, 2035:
- FDA Approval: A new drug must receive official approval from the U.S. Food and Drug Administration (FDA) specifically for the treatment of Alzheimer's disease.
- Approval means the FDA has evaluated the drug's safety and efficacy through the required clinical trial phases.
- Effectiveness: The approved drug must demonstrate the ability to slow the yearly progression of Alzheimer's disease by at least 50% compared to the standard of care.
- This reduction will be measured using standardized clinical assessments, such as cognitive function tests and daily living activity evaluations, compared to the progression rates observed with existing treatments.
- The question resolves as yes even if the effect is limited to patients with early AD.
